Primary Carnitine Deficiency
An inherited disorder of fatty acid oxidation caused by SLC22A5 gene variants, leading to impaired carnitine transport into cells, which can affect the heart, muscles, and energy metabolism.
- Newborn screening detectable
- Treatable with carnitine supplementation
- Specialist cardiac and metabolic monitoring
- Inheritance Pattern
- Autosomal Recessive
- Affected Gene
- SLC22A5
- Detection
- Newborn Screening
- Advanced Therapies
- Carnitine Supplementation, Cardiac Monitoring
Condition Overview
Primary carnitine deficiency is an inherited disorder caused by variants in the SLC22A5 gene, which encodes the carnitine transporter responsible for moving carnitine into cells. Carnitine is essential for transporting fatty acids into mitochondria for energy production, particularly important during fasting or illness.
Without adequate functional carnitine transport, fatty acids cannot be efficiently used for energy, which can lead to low blood sugar, muscle weakness, and a form of heart muscle disease called cardiomyopathy. Presentation ranges from severe infantile cardiomyopathy and hypoglycemia to milder childhood muscle weakness, and some adults are identified only through family screening or newborn screening of their own children.
Primary carnitine deficiency is included in many newborn screening programs, allowing early identification and treatment before symptoms develop in many cases. With carnitine supplementation, most affected individuals can lead active lives, though ongoing cardiac monitoring is important.
Types and Presentations
Primary carnitine deficiency presents along a spectrum depending on age and residual transporter function.
Symptoms and Signs
Symptoms vary widely, from none at all in mildly affected adults to serious cardiac and metabolic crises in infants.
Causes and Risk Factors
Primary carnitine deficiency is caused by inherited loss-of-function variants in the SLC22A5 gene, with severity influenced by residual transporter activity and metabolic stress.
Diagnosis and Investigations
Diagnosis combines biochemical carnitine testing, genetic confirmation, and cardiac evaluation.
Risk Stratification
Rather than a formal staging system, primary carnitine deficiency is risk-stratified by clinical severity and cardiac involvement at diagnosis.
Standard Treatment Approach
Treatment centers on lifelong carnitine supplementation, dietary guidance, and avoidance of prolonged fasting, with cardiac monitoring for those with cardiomyopathy.
Advanced and Emerging Treatment Options
Most individuals respond well to carnitine supplementation; emerging approaches focus on optimized dosing and earlier detection.
Metabolic Replacement
High-dose oral L-carnitine
The mainstay of treatment, dosed to normalize plasma carnitine levels and reverse cardiomyopathy when present.
Precision Medicine
Genotype-informed counseling
SLC22A5 genotype can help anticipate severity and guide family screening.
Cardiac Therapy
Heart failure management when indicated
Standard cardiomyopathy therapies may be used alongside carnitine supplementation in those with significant cardiac involvement.
Research
Newborn screening expansion programs
Ongoing public health research efforts aim to expand universal newborn screening for carnitine transporter defects.
Biomarkers and Precision Monitoring
Plasma carnitine levels and cardiac imaging are the central markers used to guide diagnosis and ongoing management.
When a Second Opinion May Be Important
A specialist metabolic or cardiology second opinion can be valuable in several situations.
Clinical Trials and Research
Prognosis and Key Outcome Factors
With early diagnosis and consistent carnitine supplementation, most individuals with primary carnitine deficiency have favorable outcomes, including reversal of cardiomyopathy in many cases.
Supportive Care and Living With Primary Carnitine Deficiency
Day-to-day management focuses on consistent supplementation, illness planning, and ongoing monitoring.
How CancerFax Helps You Explore Treatment Options
CancerFax helps connect patients and families with metabolic specialists experienced in carnitine transporter disorders and supports coordination of cardiac and genetic follow-up care.
Get a free case reviewFrequently Asked Questions
Primary carnitine deficiency is an inherited disorder caused by SLC22A5 gene variants that impair carnitine transport into cells, affecting the body's ability to use fatty acids for energy.
Signs can include muscle weakness, fatigue, poor weight gain in infants, or low blood sugar episodes, though many people are identified through newborn screening before symptoms appear.
Yes, it is included in many newborn screening programs, which measure free carnitine levels in the blood.
Treatment involves lifelong oral L-carnitine supplementation, along with guidance to avoid prolonged fasting.
Yes, it can cause dilated cardiomyopathy, which often improves with consistent carnitine supplementation.
Yes, it is inherited in an autosomal recessive pattern, meaning both parents typically carry one altered gene copy.
Yes, some adults are identified only after a relative, often their own newborn, is diagnosed through screening.
Prolonged fasting can increase risk of hypoglycemia and metabolic stress, so regular meal timing and a sick-day plan are important.
Yes, carnitine supplementation is typically continued lifelong to maintain normal carnitine levels and cardiac function.
Yes. CancerFax can help review your medical reports, coordinate a second opinion with metabolic and cardiology specialists, and help identify centers experienced in managing carnitine transporter disorders, including cross-border coordination where needed.
Managing Primary Carnitine Deficiency?
Get coordinated specialist support for carnitine supplementation and cardiac monitoring.